Concerns about the health of the European economy sent the markets tumbling in late afternoon trading with the Dow plunging 115 points to 9816. Nasdaq plummeted 45 points to 2173.
On the upside
Celgene (Nasdaq: CELG) presented data from a Phase II study of lenalidomide at the American Society of Clinical Oncology annual meeting.
Morgan Stanley upgraded Eagle Bulk Shipping (Nasdaq: EGLE).
Tenet Healthcare (NYSE: THC) ended discussions to acquire Australian hospital operator Healthscope.
On the downside
Cyclacel Pharmaceuticals (Nasdaq: CYCC) presented interim data from a Phase 2 clinical trial of its treatment for myelodysplastic syndromes that have failed hypomethylating agents.
Grubb & Ellis (NYSE: GBE) will offer 16.04 million common shares.
Hellenic Telecom (NYSE: OTE) slashed its dividend.
In the broad market, declining issues outpaced advancers by a margin of more than 5 to 2 on the NYSE and by nearly 5 to 1 on Nasdaq. The Russell 2000 which tracks small cap stocks plunged 15 points to 618.
